Announcement Date: April 14, 2016
April 14, 2016 – Study published in the Journal of the American Society of Nephrology (JASN) finds a 28% increased risk of CKD and end-stage renal disease (ESRD) with PPIs compared to H2 blockers (Pepcid, Zantac, Tagamet).